Regeneron Pharmaceuticals (NASDAQ: REGN) net income
Regeneron Pharmaceuticals reported a net profit of $4,505m for fiscal 2025, 2.1% more than in fiscal 2024 ($4,413m). Its net margin was 31.4%. Earnings per share were $43.07.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | $4,505m | +2.1% | 31.4% | $43.07 |
| 2024 | $4,413m | +11.6% | 31.1% | $40.90 |
| 2023 | $3,954m | −8.9% | 30.1% | $37.05 |
| 2022 | $4,338m | −46.3% | 35.6% | $40.51 |
| 2021 | $8,075m | +129.9% | 50.2% | $76.40 |
| 2020 | $3,513m | +66.0% | 41.3% | $32.65 |
| 2019 | $2,116m | −13.4% | 32.3% | $19.38 |
| 2018 | $2,444m | +104.0% | 47.5% | $22.65 |
| 2017 | $1,199m | +33.8% | 20.4% | $11.27 |
| 2016 | $895.5m | — | 18.4% | $8.55 |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Questions about the net income of Regeneron Pharmaceuticals
- How much did Regeneron Pharmaceuticals earn in fiscal 2025?
- Regeneron Pharmaceuticals reported a net profit of $4,505m for fiscal 2025. In fiscal 2024 it reported a net profit of $4,413m.
- What are the earnings per share of Regeneron Pharmaceuticals?
- They were $43.07 in fiscal 2025, compared with $40.90 in fiscal 2024.
- What is the net margin of Regeneron Pharmaceuticals?
- In fiscal 2025 its net profit was 31.4% of its revenue.
- What was the most profitable year for Regeneron Pharmaceuticals?
- Of its last 10 fiscal years, fiscal 2021, with $8,075m.
- Where do the figures for Regeneron Pharmaceuticals come from?
- From the annual report (Form 10-K) that Regeneron Pharmaceuticals files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Regeneron Pharmaceuticals files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on Regeneron Pharmaceuticals: the Regeneron Pharmaceuticals page · annual accounts · revenue · dividends paid · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.